We Accelerate Discovery

You are here



Medicine and Molecules

The Common Fund’s Regulatory Science program, initiated in fiscal year 2010 as a partnership between NIH and the U. S. Food and Drug Administration (FDA), aims to foster regulatory science, a specialized and inter-disciplinary area of biomedical research that serves to generate new knowledge and tools for assessing experimental therapies, preventives and diagnostics. A key goal of the Regulatory Science program is to accelerate the development and use of new tools, standards and approaches to efficiently develop products and to more effectively evaluate product safety, efficacy and quality.

The initial phase of the program provided support for four new research awards in high priority areas of regulatory science, including adaptive clinical trial design, a novel strategy to predict eye irritancy, a heart-lung model to test the safety and efficacy of drugs, and nanoparticle characterization. (View the funded research)

In 2011, the NIH Common Fund and the National Institute of Neurological Disorders and Stroke led the trans-NIH effort to establish the NIH Microphysiological Systems (Tissue Chip for Drug Screening) program, which now is led by the National Center for Advancing Translational Sciences (NCATS). The NIH Common Fund and NCATS Cures Acceleration Network fund the program. This initiative is the result of collaborations that focus the resources and ingenuity of the NIH, Defense Advanced Research Projects Agency (DARPA) and FDA.

Current methods of assessing drug safety and efficacy in pre-clinical animal models are expensive, time-consuming, and many times do not accurately predict results in humans. The Tissue Chip program aims to develop 3-D human tissues on chips that accurately model the structure and function of human organs, such as the lung, liver and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. Reducing the time and cost associated with the pre-clinical phase of drug testing may go a long way toward streamlining the drug development pipeline.

Read the press release from NIH Director announcing NIH-DARPA-FDA collaboration.
Read the press release announcing the funding of 17 new Tissue Chip for Drug Screening grants.

The latest initiative the Common Fund’s Regulatory Science program is funding is NCATS Discovering New Therapeutic Uses for Existing Molecules (Therapeutics Discovery) program. NCATS launched this collaborative pilot program in 2012 to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutic development. This innovative program matches researchers with a selection of molecular compounds from industry to test ideas for new treatments for patients. NCATS plans to issue awards in the spring of 2013.

Eight companies collaborated with NCATS to make the Therapeutics Discovery program possible: AbbVie (formerly Abbott), AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, L.L.C., Pfizer and Sanofi.

Read the press release announcing the Therapeutics Discovery program.

Read the press release announcing the addition of five companies to the Therapeutics Discovery program.

Up to Top